Achieve Life Sciences (FRA:SP4P) ROCE % : -194.83% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Achieve Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Achieve Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -194.83%.

Achieve Life Sciences ROCE % Historical Data

The historical data trend for Achieve Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences ROCE % Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-98.22

-51.41

-85.37

-166.74

-751.38

Achieve Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-324.35	-751.72	-231.85	-111.62	-194.83

Achieve Life Sciences ROCE % Calculation

Achieve Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-24.724	/	( ( (28.293 - 20.389)	+	(17.763 - 19.086) )	/ 2 )
	=	-24.724	/	( (7.904	+	-1.323)	/ 2 )
	=	-24.724	/	3.2905
	=	-751.38 %

Achieve Life Sciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-17.2	/	( ( (22.804 - 3.825)	+	(17.763 - 19.086) )	/ 2 )
	=	-17.2	/	( ( 18.979	+	-1.323 )	/ 2 )
	=	-17.2	/	8.828
	=	-194.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Achieve Life Sciences (FRA:SP4P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Achieve Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences (FRA:SP4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (FRA:SP4P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ACHV:USA

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (FRA:SP4P) Headlines

No Headlines